Developer docs
API playgroundTry for free, no card

Search company profiles

Feldan Therapeutics

Full company profile

uuid0000s6e

Namestring
Feldan Therapeutics
Legal namestring
Feldan Therapeutics, Inc.
Websiteurl
feldan.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Feldan Therapeutics is a clinical-stage biotech company headquartered in Quebec City, Canada, developing therapeutics based on intracellular delivery of biological cargo. Its core asset is the Feldan Shuttle, a proprietary peptide-based platform that enables safe, rapid, and efficient endosomal escape and delivery of antisense oligonucleotides (ASOs), proteins, CRISPR nucleases, transcription factors, and antibodies into cells, unlocking intracellular targets otherwise inaccessible to therapeutic molecules. The platform is applicable across both ex vivo and in vivo settings and has been validated in peer-reviewed Nature and Nature Communications publications.

Feldan translates the platform into a focused pipeline. Its lead candidate, FLD-103, is a non-surgical intralesional treatment for basal cell carcinoma, the most common skin cancer, and is currently in a Phase 1/2a clinical trial running across Quebec and Sydney, Australia. Its second candidate, FLD-201, is an inhaled therapy targeting mucus-driven pulmonary diseases including non-cystic fibrosis bronchiectasis (NCFB) and chronic bronchitis, currently in preclinical development. The platform's third commercial vector is an exclusive 2018 license to GC LabCell for NK cell-based cancer immunotherapy.

The company is pre-revenue, with economics expected to come from a combination of licensing agreements, milestone payments, royalties, and direct commercialization of approved products. Its go-to-market approach relies on enterprise partnerships with pharmaceutical companies (Amgen, Takeda, Sanofi, GSK, Janssen), strategic licensing deals (GC LabCell), and non-dilutive grant funding from Canadian federal programs (NSERC, NRC IRAP, CQDM) and disease foundations (Cystic Fibrosis Foundation, NIH SCGE). As of late 2024, Feldan has raised approximately US$35.3 million in disclosed equity across its Series A and Series B rounds, with Genesys Capital and Fonds de solidarité FTQ co-leading the most recent US$21M Series B completed in September 2024.

Short descriptiontext

Feldan Therapeutics is a clinical-stage biotech developing intracellular therapeutics based on its proprietary Feldan Shuttle peptide delivery platform, with lead candidate FLD-103 in Phase 1/2a trials for non-surgical basal cell carcinoma treatment and preclinical pulmonary programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersQuebec, Canada
HQ citystring
Quebec
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intracellular drug delivery, peptide-based therapeutics, antisense oligonucleotide delivery, biopharmaceutical development, CRISPR delivery technology
Industry3 codes
PRIMARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals / Intracellular Delivery Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Therapeutic Product Development
TypeOne Time License
Description

Pre-revenue clinical-stage biotech developing proprietary therapeutics. Revenue will come from product sales upon regulatory approval. Currently advancing FLD-103 for BCC through clinical trials.

newswire.ca
2Technology Licensing
TypeLicensing Royalties
Description

Licensing Feldan Shuttle technology to partners for specific therapeutic applications. GC LabCell licensed the technology for NK cell-based cancer immunotherapy development, receiving milestone payments and royalties on commercialized products.

feldan.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Feldan Therapeutics develops and commercializes the Feldan Shuttle, a proprietary peptide-based intracellular delivery technology that enables therapeutic cargo (antisense oligonucleotides, proteins, CRISPR nucleases, transcription factors, antibodies) to escape endosomes and reach intracellular targets. The company is advancing therapeutic candidates including FLD-103, a non-surgical intralesional treatment for basal cell carcinoma in Phase 1/2a trials, and FLD-201, an inhaled therapy for mucus-driven pulmonary diseases in preclinical development. The technology is also licensed to pharmaceutical partners such as GC LabCell for NK cell-based cancer immunotherapy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Phase 1/2a clinical trial initiated for FLD-103 in basal cell carcinoma (October 2024)
Product overview1 text field

Feldan Therapeutics is a clinical-stage biotech company operating as a single-platform developer: its proprietary Feldan Shuttle peptide-based technology is the core enabler, applied across a portfolio of therapeutic programs. The product portfolio consists of the Feldan Shuttle platform and two named pipeline candidates — FLD-103 (an intralesional non-surgical treatment for basal cell carcinoma in Phase 1/2a clinical trials) and FLD-201 (an inhaled therapy for mucus-driven lung diseases in preclinical development). The Feldan Shuttle enables intracellular delivery of antisense oligonucleotides, proteins, and CRISPR nucleases, allowing previously inaccessible intracellular targets to be addressed in skin and lung diseases.

Product and service3 records
1Feldan Shuttle Platform
CategoryDrug Delivery Technology Platform
Description

A proprietary peptide-based intracellular delivery technology that enables safe, rapid, and efficient local delivery of antisense oligonucleotides (ASO), proteins, CRISPR nucleases, and other therapeutic cargo into cells, unlocking intracellular targets that are otherwise beyond reach. Applicable for ex vivo and in vivo use across skin and lung disease applications. Licensed to partners including GC LabCell.

2FLD-103
CategoryOncology Therapeutic Candidate
Description

A non-surgical intralesional treatment for basal cell carcinoma (BCC), the most common form of skin cancer. FLD-103 is delivered directly into tumor lesions using the Feldan Shuttle platform and is in Phase 1/2a clinical trials.

3FLD-201
CategoryPulmonary Therapeutic Candidate
Description

An inhaled therapy targeting mucus-driven lung diseases such as non-cystic fibrosis bronchiectasis (NCFB) and chronic bronchitis. FLD-201 is in preclinical development and leverages the Feldan Shuttle technology for pulmonary delivery to airway epithelial cells.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

NSERC-funded collaboration (CA$450,000) for development of novel intralesional therapeutic approaches targeting tumor lesions. TransBIOTech conducts in vivo experiments. Nearly decade-long partnership supporting Feldan Shuttle development.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-04-18
Description

CQDM funded $503,779 project to optimize lung drug delivery platform. Combined with Amgen and Feldan contributions totaling $1,427,757 for collaborative development.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-04-18
Description

Collaborating with CQDM and Feldan on lung disease drug delivery technology optimization. Part of broader Quantum Leap project for Feldan Shuttle enhancement. Amgen Ventures also an investor.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-10-28
Description

Long-term collaboration on lung delivery research. Dr. McCray is expert in respiratory cell biology and cystic fibrosis treatment. Joint NIH-funded projects worth $4M for CRISPR delivery to airway epithelia.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-06-04
Description

Joined Quantum Leap project led by CQDM and Feldan. Japanese pharmaceutical company participating in consortium to improve Feldan Shuttle technology.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-06-27
Description

Exclusive license agreement for Feldan Shuttle in NK cell-based cancer immunotherapy development. GC LabCell developing enhanced NK cells for adoptive cell therapy. Feldan receives milestone payments and royalties on commercialized products.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics including mRNA, siRNA, and CRISPR cargo. Direct comparable as a non-viral intracellular delivery platform enabling therapeutic payloads to reach intracellular targets.

TypeDirect peer
Description

LNP-based nucleic acid delivery technology company developing RNA-based therapeutics. Directly comparable as a platform delivery company monetizing technology through partnerships and licensing across multiple therapeutic areas.

TypeDirect peer
Description

Developer of non-viral lipid nanoparticle delivery platform for DNA and RNA therapeutics targeting genetic diseases. Comparable as a non-viral delivery platform company addressing intracellular delivery challenges for nucleic acid cargo.

TypeDirect peer
Description

Clinical-stage mRNA medicines company with proprietary LNP delivery technology and pipeline spanning vaccines, protein replacement, and rare diseases. Comparable as a nucleic acid delivery and therapeutics company with similar platform-plus-product model.

TypeDirect peer
Description

Clinical-stage in vivo gene editing company developing single-course treatments for cardiovascular disease using base editing. Comparable as a company using novel delivery approaches to enable intracellular gene editing therapeutics.

TypeDirect peer
Description

Clinical-stage base editing company developing precision genetic medicines delivered via LNPs and electroporation. Comparable in its reliance on non-viral delivery approaches to enable intracellular editing therapeutics.

TypeBroad incumbent
Description

Global mRNA therapeutics and LNP delivery powerhouse with validated COVID-19 vaccine franchise and broad oncology pipeline. Comparable as a large-scale mRNA delivery and therapeutics company, though far broader and more commercially advanced than Feldan.

TypeBroad incumbent
Description

Commercial-stage mRNA medicines company with proprietary LNP delivery platform and broad pipeline across infectious disease, oncology, and rare diseases. Comparable as a leading nucleic acid delivery platform, though operating at vastly larger scale.

9Translate Bio (Sanofi)
TypeBroad incumbent
Description

Acquired by Sanofi in 2021, Translate Bio developed mRNA therapeutics with inhaled delivery for cystic fibrosis and other pulmonary diseases. Comparable to Feldan's pulmonary delivery ambitions for FLD-201 and CF application.

10ReCode Therapeutics
TypeEmerging player
Description

Clinical-stage genetic medicines company with proprietary lipid nanoparticle delivery technology targeting lung and liver diseases including cystic fibrosis and primary ciliary dyskinesia. Closely comparable to Feldan's pulmonary delivery focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Feldan Therapeutics

Biopharmaceuticals / Intracellular Delivery Therapeuticsfeldan.com

Feldan Therapeutics is a clinical-stage biotech developing intracellular therapeutics based on its proprietary Feldan Shuttle peptide delivery platform, with lead candidate FLD-103 in Phase 1/2a trials for non-surgical basal cell carcinoma treatment and preclinical pulmonary programs.

What Feldan Therapeutics does

Feldan Therapeutics is a clinical-stage biotech company headquartered in Quebec City, Canada, developing therapeutics based on intracellular delivery of biological cargo. Its core asset is the Feldan Shuttle, a proprietary peptide-based platform that enables safe, rapid, and efficient endosomal escape and delivery of antisense oligonucleotides (ASOs), proteins, CRISPR nucleases, transcription factors, and antibodies into cells, unlocking intracellular targets otherwise inaccessible to therapeutic molecules. The platform is applicable across both ex vivo and in vivo settings and has been validated in peer-reviewed Nature and Nature Communications publications.

Feldan translates the platform into a focused pipeline. Its lead candidate, FLD-103, is a non-surgical intralesional treatment for basal cell carcinoma, the most common skin cancer, and is currently in a Phase 1/2a clinical trial running across Quebec and Sydney, Australia. Its second candidate, FLD-201, is an inhaled therapy targeting mucus-driven pulmonary diseases including non-cystic fibrosis bronchiectasis (NCFB) and chronic bronchitis, currently in preclinical development. The platform's third commercial vector is an exclusive 2018 license to GC LabCell for NK cell-based cancer immunotherapy.

The company is pre-revenue, with economics expected to come from a combination of licensing agreements, milestone payments, royalties, and direct commercialization of approved products. Its go-to-market approach relies on enterprise partnerships with pharmaceutical companies (Amgen, Takeda, Sanofi, GSK, Janssen), strategic licensing deals (GC LabCell), and non-dilutive grant funding from Canadian federal programs (NSERC, NRC IRAP, CQDM) and disease foundations (Cystic Fibrosis Foundation, NIH SCGE). As of late 2024, Feldan has raised approximately US$35.3 million in disclosed equity across its Series A and Series B rounds, with Genesys Capital and Fonds de solidarité FTQ co-leading the most recent US$21M Series B completed in September 2024.

Feldan Therapeutics firmographics

Firmographics
Name
Feldan Therapeutics
Legal name
Feldan Therapeutics, Inc.
Website
https://feldan.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Feldan Therapeutics is a clinical-stage biotech developing intracellular therapeutics based on its proprietary Feldan Shuttle peptide delivery platform, with lead candidate FLD-103 in Phase 1/2a trials for non-surgical basal cell carcinoma treatment and preclinical pulmonary programs.
Ownership category
akta.pro rank

Feldan Therapeutics industry classification

Industry
Product category
Biopharmaceuticals / Intracellular Delivery Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Intracellular drug delivery
  • Peptide-based therapeutics
  • Antisense oligonucleotide delivery
  • Biopharmaceutical development
  • CRISPR delivery technology

Where Feldan Therapeutics is headquartered

Location

Headquarters

HQ city
Quebec
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Feldan Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Therapeutic Product Development: Pre-revenue clinical-stage biotech developing proprietary therapeutics. Revenue will come from product sales upon regulatory approval. Currently advancing FLD-103 for BCC through clinical trials.
  2. Technology Licensing: Licensing Feldan Shuttle technology to partners for specific therapeutic applications. GC LabCell licensed the technology for NK cell-based cancer immunotherapy development, receiving milestone payments and royalties on commercialized products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Feldan Therapeutics product offering

Product offering

Core offering

Feldan Therapeutics develops and commercializes the Feldan Shuttle, a proprietary peptide-based intracellular delivery technology that enables therapeutic cargo (antisense oligonucleotides, proteins, CRISPR nucleases, transcription factors, antibodies) to escape endosomes and reach intracellular targets. The company is advancing therapeutic candidates including FLD-103, a non-surgical intralesional treatment for basal cell carcinoma in Phase 1/2a trials, and FLD-201, an inhaled therapy for mucus-driven pulmonary diseases in preclinical development. The technology is also licensed to pharmaceutical partners such as GC LabCell for NK cell-based cancer immunotherapy.

Product overview

Feldan Therapeutics is a clinical-stage biotech company operating as a single-platform developer: its proprietary Feldan Shuttle peptide-based technology is the core enabler, applied across a portfolio of therapeutic programs. The product portfolio consists of the Feldan Shuttle platform and two named pipeline candidates — FLD-103 (an intralesional non-surgical treatment for basal cell carcinoma in Phase 1/2a clinical trials) and FLD-201 (an inhaled therapy for mucus-driven lung diseases in preclinical development). The Feldan Shuttle enables intracellular delivery of antisense oligonucleotides, proteins, and CRISPR nucleases, allowing previously inaccessible intracellular targets to be addressed in skin and lung diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Feldan Shuttle Platform A proprietary peptide-based intracellular delivery technology that enables safe, rapid, and efficient local delivery of antisense oligonucleotides (ASO), proteins, CRISPR nucleases, and other therapeutic cargo into cells, unlocking intracellular targets that are otherwise beyond reach. Applicable for ex vivo and in vivo use across skin and lung disease applications. Licensed to partners including GC LabCell.
  • FLD-103 A non-surgical intralesional treatment for basal cell carcinoma (BCC), the most common form of skin cancer. FLD-103 is delivered directly into tumor lesions using the Feldan Shuttle platform and is in Phase 1/2a clinical trials.
  • FLD-201 An inhaled therapy targeting mucus-driven lung diseases such as non-cystic fibrosis bronchiectasis (NCFB) and chronic bronchitis. FLD-201 is in preclinical development and leverages the Feldan Shuttle technology for pulmonary delivery to airway epithelial cells.

Quantifiable outcome

  • Phase 1/2a clinical trial initiated for FLD-103 in basal cell carcinoma (October 2024)

Companies that use Feldan Therapeutics

Customer profile

Segments2 records

Ideal customer profiles3 records

Feldan Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Feldan Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered major.

  • TransBIOTechmajorStrategic or Co-development Partner · 12 March 2026NSERC-funded collaboration (CA$450,000) for development of novel intralesional therapeutic approaches targeting tumor lesions. TransBIOTech conducts in vivo experiments. Nearly decade-long partnership supporting Feldan Shuttle development.
  • CQDMmajorStrategic or Co-development Partner · 18 April 2023CQDM funded $503,779 project to optimize lung drug delivery platform. Combined with Amgen and Feldan contributions totaling $1,427,757 for collaborative development.
  • AmgenmajorStrategic or Co-development Partner · 18 April 2023Collaborating with CQDM and Feldan on lung disease drug delivery technology optimization. Part of broader Quantum Leap project for Feldan Shuttle enhancement. Amgen Ventures also an investor.
  • University of Iowa (Dr. Paul McCray)majorStrategic or Co-development Partner · 28 October 2019Long-term collaboration on lung delivery research. Dr. McCray is expert in respiratory cell biology and cystic fibrosis treatment. Joint NIH-funded projects worth $4M for CRISPR delivery to airway epithelia.
  • TakedamajorStrategic or Co-development Partner · 4 June 2019Joined Quantum Leap project led by CQDM and Feldan. Japanese pharmaceutical company participating in consortium to improve Feldan Shuttle technology.
  • GC LabCellmajorOEM/ Whitelabel/ Licensing Partner · 27 June 2018Exclusive license agreement for Feldan Shuttle in NK cell-based cancer immunotherapy development. GC LabCell developing enhanced NK cells for adoptive cell therapy. Feldan receives milestone payments and royalties on commercialized products.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Feldan Therapeutics competitors and assessment

Company assessment

Direct peers

  • Acuitas Therapeutics: Developer of lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics including mRNA, siRNA, and CRISPR cargo. Direct comparable as a non-viral intracellular delivery platform enabling therapeutic payloads to reach intracellular targets.
  • Genevant Sciences: LNP-based nucleic acid delivery technology company developing RNA-based therapeutics. Directly comparable as a platform delivery company monetizing technology through partnerships and licensing across multiple therapeutic areas.
  • Generation Bio: Developer of non-viral lipid nanoparticle delivery platform for DNA and RNA therapeutics targeting genetic diseases. Comparable as a non-viral delivery platform company addressing intracellular delivery challenges for nucleic acid cargo.
  • Arcturus Therapeutics: Clinical-stage mRNA medicines company with proprietary LNP delivery technology and pipeline spanning vaccines, protein replacement, and rare diseases. Comparable as a nucleic acid delivery and therapeutics company with similar platform-plus-product model.
  • Verve Therapeutics: Clinical-stage in vivo gene editing company developing single-course treatments for cardiovascular disease using base editing. Comparable as a company using novel delivery approaches to enable intracellular gene editing therapeutics.
  • Beam Therapeutics: Clinical-stage base editing company developing precision genetic medicines delivered via LNPs and electroporation. Comparable in its reliance on non-viral delivery approaches to enable intracellular editing therapeutics.

Broad incumbents

  • BioNTech: Global mRNA therapeutics and LNP delivery powerhouse with validated COVID-19 vaccine franchise and broad oncology pipeline. Comparable as a large-scale mRNA delivery and therapeutics company, though far broader and more commercially advanced than Feldan.
  • Moderna: Commercial-stage mRNA medicines company with proprietary LNP delivery platform and broad pipeline across infectious disease, oncology, and rare diseases. Comparable as a leading nucleic acid delivery platform, though operating at vastly larger scale.
  • Translate Bio (Sanofi): Acquired by Sanofi in 2021, Translate Bio developed mRNA therapeutics with inhaled delivery for cystic fibrosis and other pulmonary diseases. Comparable to Feldan's pulmonary delivery ambitions for FLD-201 and CF application.

Emerging players

  • ReCode Therapeutics: Clinical-stage genetic medicines company with proprietary lipid nanoparticle delivery technology targeting lung and liver diseases including cystic fibrosis and primary ciliary dyskinesia. Closely comparable to Feldan's pulmonary delivery focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Feldan Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Feldan Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Feldan Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Feldan Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Feldan Therapeutics

What does Feldan Therapeutics do?

Feldan Therapeutics develops and commercializes the Feldan Shuttle, a proprietary peptide-based intracellular delivery technology that enables therapeutic cargo (antisense oligonucleotides, proteins, CRISPR nucleases, transcription factors, antibodies) to escape endosomes and reach intracellular targets. The company is advancing therapeutic candidates including FLD-103, a non-surgical intralesional treatment for basal cell carcinoma in Phase 1/2a trials, and FLD-201, an inhaled therapy for mucus-driven pulmonary diseases in preclinical development. The technology is also licensed to pharmaceutical partners such as GC LabCell for NK cell-based cancer immunotherapy.

Is Feldan Therapeutics a public or private company?

Feldan Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Feldan Therapeutics founded?

Feldan Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Feldan Therapeutics based?

Feldan Therapeutics is headquartered in Quebec, Canada, in the North America region.

How does Feldan Therapeutics make money?

Two revenue lines are on record. Therapeutic Product Development is the primary driver. The others are technology Licensing.

Who are Feldan Therapeutics's main competitors?

Direct peers on record are Acuitas Therapeutics, Genevant Sciences, Generation Bio, Arcturus Therapeutics, Verve Therapeutics and Beam Therapeutics. Broad incumbents are BioNTech, Moderna and Translate Bio (Sanofi). ReCode Therapeutics is listed as an emerging player.

Does Feldan Therapeutics have an API?

No public API is recorded for Feldan Therapeutics.

What industry is Feldan Therapeutics in?

Feldan Therapeutics's product category is Biopharmaceuticals / Intracellular Delivery Therapeutics. Its primary akta.pro industry code is HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewswireFELDAN THERAPEUTICS REPORTS PRELIMINARY PHASE 1 RESULTS FOR FLD-103 IN NODULAR BASAL CELL CARCINOMA, DEMONSTRATING A GENERALLY WELL-TOLERATED SAFETY PROFILE AND SIGNS OF CLINICAL ACTIVITY IN EXPLORATORY ASSESSMENTSFeldan Therapeutics reported preliminary Phase 1 results for FLD-103 in nodular basal cell carcinoma, showing a generally well-tolerated safety profile. Exploratory assessments found a reduction of over 30% in tumor tissue in 28 of 32 treated lesions (88%), with 6 complete histological responses. The company plans to advance the program into a Phase 2 study.Private Capital JournalIndia’s Zydus invests in Feldan Therapeutics – updateZynext Ventures, the investment arm of Zydus Lifesciences, announced an investment in Feldan Therapeutics, a clinical-stage biotech developing intracellular drug delivery. Feldan's lead BCC treatment FLD-103 is in a Phase 1/2a trial, and the company closed a $21 million Series B extension in August 2024.NewswireZynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug DeliveryZynext Ventures, the venture capital arm of Zydus Lifesciences, invested in Feldan Therapeutics, a Canada-based company developing intracellular drug delivery. Feldan's lead candidate FLD-103 targets basal cell carcinoma, and the company is advancing a pulmonary program. The partnership aims to accelerate next-generation therapies for skin and lung diseases.YahooZynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug DeliveryZynext Ventures, the venture capital arm of Zydus Lifesciences, invested in Feldan Therapeutics, a Canada-based company developing intracellular drug delivery. Feldan's lead candidate FLD-103 is in a Phase 1/2a trial for basal cell carcinoma, with a pulmonary program also advancing. The partnership aims to accelerate next-generation therapies for skin and lung diseases.PR NewswireZynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug DeliveryZynext Ventures, the venture capital arm of Zydus Lifesciences, invested in Feldan Therapeutics, a Canada-based company developing intracellular drug delivery. Feldan's lead candidate FLD-103 is in a Phase 1/2a trial for basal cell carcinoma, and the company is advancing a pulmonary program. The partnership aims to accelerate next-generation therapies for skin and lung diseases.NewswireFELDAN THERAPEUTICS ACCELERATES GROWTH WITH STRATEGIC INVESTMENT FROM LINEARIS VENTURESFeldan Therapeutics announced an investment from Linearis Ventures, supported by Ville de Québec, to advance its lead candidate FLD-103 for basal cell carcinoma. The funding will support the Phase 1/2a trial and pipeline expansion, with the company also advancing a pulmonary program.NewswireFELDAN THERAPEUTICS COMPLETES A US$ 21 MILLION SERIES B FINANCING CO-LED BY GENESYS CAPITAL AND FONDS DE SOLIDARITÉ FTQFeldan Therapeutics has closed a US$ 21 million Series B financing round co-led by Genesys Capital and Fonds de solidarité FTQ, with participation from existing shareholders including Amgen Ventures. The funds will be used to complete Phase 1/2a clinical studies for FLD-103, a treatment for basal cell carcinoma, and support the preclinical development of its pulmonary program. This investment follows an earlier financing announcement in June 2023.PR NewswireFELDAN THERAPEUTICS SECURES $16.5M SERIES B TO BRING LEAD ASSET TO CLINICAL DEVELOPMENTFeldan Therapeutics has secured the initial closing of a $16.5 million Series B investment to fund clinical trials for its basal cell carcinoma treatment FLD-103 and advance its pulmonary program. New investors including Amgen Ventures, Investissement Québec, and GC Cell joined existing shareholders to support the biopharmaceutical company's development efforts.FinSMEsFeldan Therapeutics Holds Initial Closing of $16.5M Series B FundingFeldan Therapeutics closed its Series B funding round, raising $16.5 million from a group of investors including Investissement Québec and Amgen Ventures. The company plans to utilize the capital to initiate clinical phases I/II for its basal cell carcinoma treatment FLD-103 and advance its pulmonary program to the preclinical stage.